Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Intellia Therapeutics (NTLA) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Intellia Therapeutics (NTLA) lobbying for?
Summary of Lobbying Data:
Company: Intellia Therapeutics
Lobbying firms: Crossroads Strategies, Llc
General issues: Health Issues
Specific issues: The Affordable and Safe Prescription Drug Importation Act, Making consolidated appropriations for the fiscal year ending September 30, Education and advocacy related to genome editing technology; COVID-19 therapies; drug pricing; FY2022 Departments of Labor, and Related Agencies Appropriations Act (H.R.4502); S.909, Health and Human Services, 2021 and Other Extensions Act. H.R.133, More Cures Act of 2019. FY 2021 Departments of Labor, Elijah E. Cummings Lower Drug Costs Now Act, and Related Agencies Appropriations Act (H.R.4502, The Prescription Drug Price Relief Act; S.908, Education and advocacy related to genome editing technology. Education around COVID-19 therapies. H.R.3, and Education, More Cures Act of 2019. H.R.1425, The Affordable and Safe Prescription Drug Importation Act; H.R.3, and for other purposes (P.L.116-260), S.3062); S.909, FY2021 Consolidated Appropriations Act (H.R.7617), Lower Costs, More Cures Act of 2019, 2021, providing coronavirus emergency response and relief, Education and advocacy related to genome editing technology; COVID-19 therapies; drug pricing; FY2022 Departments of Labor, and Related Agencies Appropriations Act; S.909, and Related Agencies Appropriations Act (H.R.7614), The Medicare Drug Price Negotiation Act; S.920, Education and advocacy related to gene therapy. Education around COVID-19 therapies. H.R.3, and Related Agencies Appropriations. H.R.1425, Patient Protection and Affordable Care Enhancement Act. FY2021 Departments of Labor, Continuing Appropriations Act, H.R.8337, Prescription Drug Pricing Reduction Act of 2019. H.R.19, and Related Agencies Appropriations Act; S.909, Lower Drug Costs Now Act of 2019. S.2543, State Health Care Premium Reduction Act. 2021 and Other Extensions Act.
Government agencies: Office of the Vice President of the United States, House of Representatives, Food & Drug Administration (FDA), Senate, Executive Office of the President (EOP)
One could infer that Intellia Therapeutics is lobbying on health issues with a focus on drug pricing, COVID-19 therapies and genome editing technology, as these are relevant to their business operations as a biotechnology company that specializes in developing gene therapies using CRISPR technology. Furthermore, they are lobbying on legislation related to prescription drug pricing and importation, as this is an important issue for the pharmaceutical industry as a whole. The company is also likely seeking to influence lawmakers to provide funding for research and development of new therapies, which is reflected in their lobbying efforts around the FY2022 Departments of Labor and Related Agencies Appropriations Act.
